Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications.

Wiltshire RN, Herndon JE 2nd, Lloyd A, Friedman HS, Bigner DD, Bigner SH, McLendon RE.

J Mol Diagn. 2004 Aug;6(3):166-79.

2.

Molecular markers of prognosis in astrocytic tumors.

Rasheed A, Herndon JE, Stenzel TT, Raetz JG, Kendelhardt J, Friedman HS, Friedman AH, Bigner DD, Bigner SH, McLendon RE.

Cancer. 2002 May 15;94(10):2688-97.

3.

MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group.

Aldosari N, Bigner SH, Burger PC, Becker L, Kepner JL, Friedman HS, McLendon RE.

Arch Pathol Lab Med. 2002 May;126(5):540-4.

PMID:
11958658
4.

Comprehensive molecular cytogenetic investigation of chromosomal abnormalities in human medulloblastoma cell lines and xenograft.

Aldosari N, Wiltshire RN, Dutra A, Schrock E, McLendon RE, Friedman HS, Bigner DD, Bigner SH.

Neuro Oncol. 2002 Apr;4(2):75-85. doi: 10.1093/neuonc/4.2.75.

5.

High rate of CAD gene amplification in human cells deficient in MLH1 or MSH6.

Chen S, Bigner SH, Modrich P.

Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13802-7.

6.

Morphologic and molecular genetic aspects of oligodendroglial neoplasms.

Bigner SH, Rasheed BK, Wiltshire R, McLendon RE.

Neuro Oncol. 1999 Jan;1(1):52-60. doi: 10.1093/neuonc/1.1.52. Review.

7.

Comparative genetic patterns of glioblastoma multiforme: potential diagnostic tool for tumor classification.

Wiltshire RN, Rasheed BK, Friedman HS, Friedman AH, Bigner SH.

Neuro Oncol. 2000 Jul;2(3):164-73. doi: 10.1093/neuonc/2.3.164.

8.

Ham56-immunoreactive macrophages in untreated infiltrating gliomas.

Cummings TJ, Hulette CM, Bigner SH, Riggins GJ, McLendon RE.

Arch Pathol Lab Med. 2001 May;125(5):637-41.

PMID:
11300934
9.

Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.

Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner SH, Zhao XG, Garcia-Turner AM, Pegram CN, Wikstrand CJ, Shafman TD, Herndon JE 2nd, Provenzale JM, Zalutsky MR, Bigner DD.

J Clin Oncol. 2000 Nov 15;18(22):3862-72.

PMID:
11078500
10.

Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor.

McLendon RE, Wikstrand CJ, Matthews MR, Al-Baradei R, Bigner SH, Bigner DD.

J Histochem Cytochem. 2000 Aug;48(8):1103-10.

PMID:
10898803
12.

Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis.

Cummings TJ, Provenzale JM, Hunter SB, Friedman AH, Klintworth GK, Bigner SH, McLendon RE.

Acta Neuropathol. 2000 May;99(5):563-70.

PMID:
10805102
13.

Characterization of chromosome 17 abnormalities in medulloblastomas.

Aldosari N, Rasheed BK, McLendon RE, Friedman HS, Bigner DD, Bigner SH.

Acta Neuropathol. 2000 Apr;99(4):345-51.

PMID:
10787031
14.

Evaluation of an automated technique for assessment of marrow engraftment after allogeneic bone marrow transplantation using a commercially available kit.

Nuckols JD, Rasheed BK, McGlennen RC, Bigner SH, Stenzel TT.

Am J Clin Pathol. 2000 Jan;113(1):135-40.

PMID:
10631867
15.

Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.

Bigner SH, Matthews MR, Rasheed BK, Wiltshire RN, Friedman HS, Friedman AH, Stenzel TT, Dawes DM, McLendon RE, Bigner DD.

Am J Pathol. 1999 Aug;155(2):375-86.

16.

Molecular pathogenesis of malignant gliomas.

Rasheed BK, Wiltshire RN, Bigner SH, Bigner DD.

Curr Opin Oncol. 1999 May;11(3):162-7. Review.

PMID:
10328589
17.

Diagnostic markers in paediatric medulloblastoma: a Paediatric Oncology Group Study.

McLendon RE, Friedman HS, Fuchs HE, Kun LE, Bigner SH.

Histopathology. 1999 Feb;34(2):154-62.

PMID:
10064395
18.

DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.

Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, Colvin OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH, Modrich PL.

J Clin Oncol. 1998 Dec;16(12):3851-7.

PMID:
9850030
19.

Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.

Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, Pegram CN, Wikstrand CJ, Herndon JE 2nd, Vick NA, Paleologos N, Cokgor I, Provenzale JM, Zalutsky MR.

J Clin Oncol. 1998 Jun;16(6):2202-12.

PMID:
9626222
20.

Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas.

McLendon RE, Cleveland L, Pegram C, Bigner SH, Bigner DD, Friedman HS.

Lab Invest. 1998 May;78(5):643-4. No abstract available.

PMID:
9605190
21.

Multicenter masked evaluation of AutoCyte PREP thin layers with matched conventional smears. Including initial biopsy results.

Bishop JW, Bigner SH, Colgan TJ, Husain M, Howell LP, McIntosh KM, Taylor DA, Sadeghi MH.

Acta Cytol. 1998 Jan-Feb;42(1):189-97.

PMID:
9479339
22.

Molecular cytogenetics of brain tumors.

Bigner SH, Schröck E.

J Neuropathol Exp Neurol. 1997 Nov;56(11):1173-81. Review.

PMID:
9370227
23.

PTEN gene mutations are seen in high-grade but not in low-grade gliomas.

Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, Bigner DD, Bigner SH.

Cancer Res. 1997 Oct 1;57(19):4187-90.

24.

Chromosomal characteristics of childhood brain tumors.

Bigner SH, McLendon RE, Fuchs H, McKeever PE, Friedman HS.

Cancer Genet Cytogenet. 1997 Sep;97(2):125-34.

PMID:
9283596
25.

Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft.

Friedman HS, Johnson SP, Dong Q, Schold SC, Rasheed BK, Bigner SH, Ali-Osman F, Dolan E, Colvin OM, Houghton P, Germain G, Drummond JT, Keir S, Marcelli S, Bigner DD, Modrich P.

Cancer Res. 1997 Jul 15;57(14):2933-6. Erratum in: Cancer Res 1997 Nov 1;57(21):4973.

26.

Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes.

Mann KP, DeCastro CM, Liu J, Moore JO, Bigner SH, Traweek ST.

Am J Clin Pathol. 1997 Jun;107(6):653-60.

PMID:
9169661
27.

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.

Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R.

Science. 1997 Mar 28;275(5308):1943-7.

28.

Identification and characterization of neogenin, a DCC-related gene.

Meyerhardt JA, Look AT, Bigner SH, Fearon ER.

Oncogene. 1997 Mar 13;14(10):1129-36.

29.

Molecular studies of an ependymoma-associated constitutional t(1;22)(p22;q11.2).

Rhodes CH, Call KM, Budarf ML, Barnoski BL, Bell CJ, Emanuel BS, Bigner SH, Park JP, Mohandas TK.

Cytogenet Cell Genet. 1997;78(3-4):247-52.

PMID:
9465898
30.

Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.

Brown MT, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Reiman R, Felsberg GJ, Tien RD, Bigner SH, Zalutsky MR, Zhao XG, Wikstrand CJ, Pegram CN, Herndon JE 2nd, Vick NA, Paleologos N, Fredericks RK, Schold SC Jr, Bigner DD.

Clin Cancer Res. 1996 Jun;2(6):963-72.

31.

In vivo growth conditions suppress the expression of ganglioside GM2 and favour that of lacto series gangliosides in the human glioma D-54MG cell line.

Fredman P, Wikstrand CJ, Månsson JE, Reifenberger G, Bigner SH, Rasheed A, Svennerholm L, Bigner DD.

Glycoconj J. 1996 Jun;13(3):391-9.

PMID:
8781970
32.

Production and characterization of two ependymoma xenografts.

McLendon RE, Fung KM, Bentley RC, Ahmed Rasheed BK, Trojanowski JQ, Bigner SH, Bigner DD, Friedman HS.

J Neuropathol Exp Neurol. 1996 May;55(5):540-8.

PMID:
8627345
33.

Microsatellite analysis of childhood brain tumors.

Blaeker H, Rasheed BK, McLendon RE, Friedman HS, Batra SK, Fuchs HE, Bigner SH.

Genes Chromosomes Cancer. 1996 Jan;15(1):54-63.

PMID:
8824726
34.

DCC expression is altered by multiple mechanisms in brain tumours.

Ekstrand BC, Mansfield TA, Bigner SH, Fearon ER.

Oncogene. 1995 Dec 7;11(11):2393-402.

PMID:
8570191
35.

Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25.

Rasheed BK, McLendon RE, Friedman HS, Friedman AH, Fuchs HE, Bigner DD, Bigner SH.

Oncogene. 1995 Jun 1;10(11):2243-6.

PMID:
7784070
36.

Prognostic implications of chromosome 17p deletions in human medulloblastomas.

Batra SK, McLendon RE, Koo JS, Castelino-Prabhu S, Fuchs HE, Krischer JP, Friedman HS, Bigner DD, Bigner SH.

J Neurooncol. 1995;24(1):39-45.

PMID:
8523074
37.

Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.

Bigner DD, Brown M, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Bigner SH, Zhao XG, Wikstrand CJ, Pegram CN, et al.

J Neurooncol. 1995;24(1):109-22.

PMID:
8523067
38.

Cyclophosphamide therapy of medulloblastoma: from the laboratory to the clinic and back again (and again and again).

Friedman HS, Bigner SH, Bigner DD.

J Neurooncol. 1995;24(1):103-8. Review.

PMID:
8523066
39.

Deletion of p16 and p15 genes in brain tumors.

Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW, Vogelstein B.

Cancer Res. 1994 Dec 15;54(24):6353-8.

40.

Oncogenes and anti-oncogenes in human central nervous system tumors.

Batra SK, Rasheed BK, Bigner SH, Bigner DD.

Lab Invest. 1994 Nov;71(5):621-37. Review. No abstract available.

PMID:
7967518
41.

Alterations of the TP53 gene in human gliomas.

Rasheed BK, McLendon RE, Herndon JE, Friedman HS, Friedman AH, Bigner DD, Bigner SH.

Cancer Res. 1994 Mar 1;54(5):1324-30.

42.

Lack of association of human polyomaviruses with human brain tumors.

Arthur RR, Grossman SA, Ronnett BM, Bigner SH, Vogelstein B, Shah KV.

J Neurooncol. 1994;20(1):55-8.

PMID:
7807184
43.

Studies of the deleted in colorectal cancer gene in normal and neoplastic tissues.

Fearon ER, Ekstrand BC, Hu G, Pierceall WE, Reale MA, Bigner SH.

Cold Spring Harb Symp Quant Biol. 1994;59:637-43.

PMID:
7587124
44.

Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma.

Schold SC Jr, Zalutsky MR, Coleman RE, Glantz MJ, Friedman AH, Jaszczak RJ, Bigner SH, Bigner DD.

Invest Radiol. 1993 Jun;28(6):488-96.

PMID:
7686539
45.

Monoclonal antibodies to malignant human gliomas.

Wikstrand CJ, Fredman P, Svennerholm L, Humphrey PA, Bigner SH, Bigner DD.

Mol Chem Neuropathol. 1992 Oct;17(2):137-46. Review.

PMID:
1384525
46.

Application of a panel of antiganglioside monoclonal antibodies to cytologic specimens.

Vick WW, Tello JW, Wikstrand CJ, He X, Longee D, Fredman P, Svennerholm L, Bigner DD, Johnston WW, Bigner SH.

Acta Cytol. 1992 Sep-Oct;36(5):697-705.

PMID:
1523927
47.

Loss of heterozygosity for 10q loci in human gliomas.

Rasheed BK, Fuller GN, Friedman AH, Bigner DD, Bigner SH.

Genes Chromosomes Cancer. 1992 Jul;5(1):75-82.

PMID:
1384665
48.

Cerebrospinal fluid (CSF) cytology: current status and diagnostic applications.

Bigner SH.

J Neuropathol Exp Neurol. 1992 May;51(3):235-45. Review.

PMID:
1583530
49.

Amplified cellular oncogenes in neoplasms of the human central nervous system.

Fuller GN, Bigner SH.

Mutat Res. 1992 May;276(3):299-306. Review.

PMID:
1374522
50.

Structural alterations of the epidermal growth factor receptor gene in human gliomas.

Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, Vogelstein B.

Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2965-9.

Supplemental Content

Loading ...
Support Center